Fulcrum Therapeutics Recognizes Rare Disease Day 2021
Theme of global unity highlights critical role of building communities of support for patients and families affected by rare diseases around the world
February 26, 2021 07:00 ET
| Source:
Fulcrum Therapeutics
Fulcrum Therapeutics
CAMBRIDGE, Mass., Feb. 26, 2021 (GLOBE NEWSWIRE) --
Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced the company’s recognition of Rare Disease Day 2021.
“While COVID-19 has had an impact on most people around the world, it has put a new spotlight on the importance of connectivity and community for people affected by rare diseases who are at a higher risk of feelings of isolation and can face significant challenges in accessing information and healthcare services,” said Robert J. Gould, Ph.D., Fulcrum’s president and chief executive officer. “We have been privileged to work with many patients and caregivers affected by genetically defined diseases including facioscapulohumeral muscular dystrophy and sickle cell disease. They have bravely shared their stories in efforts to help others better understand these diseases and access information and support that can help.”